Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Biotech Due Diligence |
|
BiotechDueDiligence and HSP90 Central will be covering the 2013 AACR Annual Meeting live from Washington DC. This post will focus on abstracts to be presented by Astex Pharmaceuticals ASTX (partnered pipeline - see Parts 1 and 3 for internal ASTX assets), ArQule Inc ARQL, and BioSante Pharma BPAX.
Full coverage: Introduction Preview Part 1 (SNTA, ASTX, NVS, INFI) Preview Part 2 Preview Part 3 (ARRY, ASTX)
0 Comments
For archival purposes, even though it seems less and less likely that these trials will happen. Full background on Biosante Pharma BPAX and Libigel here.
Quick notes from Biosante Pharma $BPAX CEO Stephen Simes at Jefferies:
There was no conference call held by BioSante Pharma $BPAX in connection with the 2q-2012 earnings release, but a couple quick notes from their quarterly SEC filing:
Just when I think I can stop writing about BioSante Pharma $BPAX for awhile, the stock goes an pops 56% today with no apparent explanation. I'll run through a few of the spurious theories to explain the jump and discredit them. EDIT: I decided to increase the number of theories from 4 to 8 due to inspiration from @AdamFeuerstein, @Gekkowire, and others. I'll address all eight - in reverse order of plausibility! Keep reading below for the full list. |
Categories
All
Archives
January 2020
|
|
|